JAK2 and myeloproliferative neoplasm: It has been reported that an SF3B1 mutation is an early event in myeloid neoplasms, and in MDS/MPN, SF3B1 mutations seem to represent founder mutations followed by secondary hits in genes involved in other signaling pathways, such as JAK2 [17].